Diversified Trust Co Sells 79 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Diversified Trust Co reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,922 shares of the medical research company’s stock after selling 79 shares during the quarter. Diversified Trust Co’s holdings in IQVIA were worth $574,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Canada Pension Plan Investment Board increased its stake in shares of IQVIA by 6.6% during the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after buying an additional 211,653 shares during the period. Farallon Capital Management LLC increased its position in IQVIA by 3.1% during the 2nd quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock valued at $618,046,000 after purchasing an additional 86,870 shares during the period. FMR LLC raised its holdings in shares of IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after purchasing an additional 804,963 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares during the period. Finally, Impax Asset Management Group plc increased its holdings in IQVIA by 9.7% during the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock valued at $423,885,000 after buying an additional 157,809 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

IQV has been the topic of several recent research reports. Truist Financial dropped their target price on IQVIA from $265.00 to $261.00 and set a “buy” rating on the stock in a research report on Thursday, December 12th. TD Cowen cut their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Leerink Partners reiterated an “outperform” rating and issued a $248.00 target price (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Redburn Atlantic assumed coverage on shares of IQVIA in a report on Monday, October 14th. They issued a “buy” rating and a $276.00 price target on the stock. Finally, William Blair reiterated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $255.82.

IQVIA Stock Performance

IQV opened at $203.83 on Friday. The firm has a 50 day moving average of $201.84 and a two-hundred day moving average of $221.62. The firm has a market capitalization of $37.00 billion, a PE ratio of 26.75, a P/E/G ratio of 2.05 and a beta of 1.48. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.